# Adaptive Control Law Design

Design the control law that maps biomarker values to stimulation parameter adjustments, including stability analysis and safety bounds.

## Inputs

- `detection-algorithm`: Real-time biomarker output specification
- `stimulation-parameters`: Adjustable parameter range (amplitude, frequency, pulse width)
- `biomarker-characterization-data`: Biomarker-symptom correlation and stimulation response dynamics

## Outputs

- `control-law-specification`: Control algorithm (threshold, proportional, PID, model-predictive), parameter mapping function, update rate, and safety constraints
- `stability-and-safety-analysis`: Closed-loop stability verification (phase margin, gain margin), safety bound analysis, and failure mode response

## Process

1. Model the plant (brain response to stimulation). From open-loop data (step changes in stimulation amplitude while recording biomarker): identify a transfer function. For Parkinson's beta power response to STN stimulation: approximately a first-order system with gain K (beta suppression per mA of stimulation, typically 20-40%/mA) and time constant tau (0.5-2 seconds for beta onset, 1-5 seconds for offset). Include a pure time delay of 200-500 ms for neural processing. Plant model: G(s) = K x exp(-delay x s) / (1 + tau x s).
2. Design the controller. For proportional control: stimulation amplitude = K_p x (biomarker - setpoint), where setpoint is the desired biomarker level (e.g., 50th percentile of beta power distribution). Choose K_p for adequate response without oscillation: the gain margin should be at least 6 dB and phase margin at least 45 degrees. For the first-order plant with delay above: the maximum proportional gain before instability is approximately tau / (K x delay). With tau = 1 s, K = 0.3/mA, delay = 0.3 s: max K_p approximately 11 mA. Use K_p = 3-5 mA for adequate margin.
3. Add safety constraints. Hard limits: minimum stimulation amplitude = 0 (no negative stimulation), maximum amplitude = the maximum safe value from charge density analysis. Rate limits: no more than 0.5 mA change per second to prevent abrupt transitions that could cause transient side effects. If the biomarker signal quality drops (amplitude below noise floor, or artifact detected): freeze stimulation at current level for a timeout period (10-30 seconds), then ramp to a safe open-loop default. All transitions must be smooth (ramp, not step) to avoid patient discomfort.
4. Simulate the closed-loop system. Use the plant model and controller to simulate the response to: (1) step change in symptom state (e.g., medication wearing off, increasing beta), (2) biomarker noise (random fluctuations), (3) sensor dropout (biomarker signal lost for 5 seconds). Verify: no oscillations in stimulation amplitude, settling time within acceptable clinical range (under 30 seconds for Parkinson's), no overshoot beyond safety limits. Validate the simulation against actual closed-loop recordings from clinical studies if available (Adaptive DBS trials show 30-50% energy savings vs continuous stimulation with equivalent symptom control).

---

Copyright 2024-present The Wayfinder Trust. All rights reserved.
